Related references
Note: Only part of the references are listed.Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials
Steven Kwasi Korang et al.
PLOS ONE (2022)
Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021
Margaux M. Mesle et al.
EUROSURVEILLANCE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Tracy J. Ruckwardt et al.
LANCET RESPIRATORY MEDICINE (2021)
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers
Milagritos D. Tapia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial
Anna P. Durbin et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports
Lars Jorgensen et al.
SYSTEMATIC REVIEWS (2020)
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study
Geert Leroux-Roels et al.
VACCINE (2019)
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects
Stuart P. Adler et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults
Stephane Pillet et al.
PLOS ONE (2019)
Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial
Miao-Chiu Hung et al.
VACCINE (2019)
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naive adults
Susan B. Manoff et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials
Jiri Beran et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch et al.
LANCET (2018)
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
Wilbur H. Chen et al.
LANCET INFECTIOUS DISEASES (2018)
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
David Greenberg et al.
VACCINE (2018)
Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
Yu-Ju Lin et al.
SCIENTIFIC REPORTS (2018)
LB18. An Enveloped Virus-like Particle (eVLP) Cytomegalovirus (CMV) Vaccine Is Immunogenic and Safe: Results of a First-in-Humans Study
Soren Gantt et al.
Open Forum Infectious Diseases (2018)
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus (RSV) Vaccine Containing RSV SH Antigen and a Novel Adjuvant DepoVax, or SH Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50–64 Years of Age
Joanne Langley et al.
Open Forum Infectious Diseases (2017)
HPV vaccines - A review of the first decade
Diane M. Harper et al.
GYNECOLOGIC ONCOLOGY (2017)
Vaccine Ingredients: Components that Influence Vaccine Efficacy
Aneta Kocourkova et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2017)
Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial
Un-In Wu et al.
VACCINE (2017)
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Louis Fries et al.
IMMUNITY & AGEING (2017)
Industry sponsorship and research outcome
Andreas Lundh et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
Jordi Rello et al.
CRITICAL CARE (2017)
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
Gregory M. Glenn et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study
Mark S. Riddle et al.
CLINICAL AND VACCINE IMMUNOLOGY (2016)
A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women
Geert Leroux-Roels et al.
VACCINE (2016)
A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults
Eric Sheldon et al.
VACCINE (2016)
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers
Nicole Bezay et al.
VACCINE (2016)
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults
Geert Leroux-Roels et al.
VACCINE (2016)
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial
Guy de Bruyn et al.
VACCINE (2016)
Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System
Nikolai Madrid Scheller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine
Ajoke Sobanjo-ter Meulen et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus
Louise S. Brinth et al.
VACCINE (2015)
Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials
Isabel Leroux-Roels et al.
VACCINE (2015)
Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study
W. Abdullah Brooks et al.
VACCINE (2015)
Canadian academic's call for moratorium on HPV vaccine sparks controversy
Owen Dyer
BMJ-BRITISH MEDICAL JOURNAL (2015)
Canadian academic's call for moratorium on HPV vaccine sparks controversy
Owen Dyer
BMJ-BRITISH MEDICAL JOURNAL (2015)
Shared Sanitation and the Prevalence of Diarrhea in Young Children: Evidence from 51 Countries, 2001-2011
James A. Fuller et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2014)
Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods
Janus Christian Jakobsen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Vaccines for the 21st century
Isabel Delany et al.
EMBO MOLECULAR MEDICINE (2014)
Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects
L. Grimaldi-Bensouda et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults
James F. Cummings et al.
VACCINE (2014)
Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population
Jacob Atsmon et al.
VACCINE (2014)
Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies
V. H. Basavaraj et al.
VACCINE (2014)
Safety and immunogenicity of a virus-like, particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers
Jenny G. H. Low et al.
VACCINE (2014)
Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants
Pauline Verdijk et al.
VACCINE (2014)
A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprE/I vaccine (IC43) in healthy volunteers
Kerstin Westritschnig et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial
Christine Juergens et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: A Phase I trial in Taiwan
Sung-Ching Pan et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2013)
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
Nina Wressnigg et al.
LANCET INFECTIOUS DISEASES (2013)
Key roles of adjuvants in modern vaccines
Steven G. Reed et al.
NATURE MEDICINE (2013)
Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults
Pauline Verdijk et al.
VACCINE (2013)
Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK
Katherine Donegan et al.
VACCINE (2013)
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
Gregory M. Glenn et al.
VACCINE (2013)
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
An-Wen Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study
Lisen Arnheim-Dahlstrom et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Mechanisms of action of adjuvants
Sunita Awate et al.
FRONTIERS IN IMMUNOLOGY (2013)
Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females
Nicola P. Klein et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2012)
Phase 1 Study of a Recombinant Mutant Protective Antigen of Bacillus anthracis
Joseph A. Bellanti et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Phase IIa Study of the Immunogenicity and Safety of the Novel Staphylococcus aureus Vaccine V710 in Adults with End-Stage Renal Disease Receiving Hemodialysis
Moustafa Moustafa et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Too Fast or Not Too Fast: The FDA's Approval of Merck's HPV Vaccine Gardasil
Lucija Tomljenovic et al.
JOURNAL OF LAW MEDICINE & ETHICS (2012)
Alum adjuvant: some of the tricks of the oldest adjuvant
Mirjam Kool et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2012)
The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies
Clayton D. Harro et al.
VACCINE (2012)
Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine
Monica Bologa et al.
VACCINE (2012)
Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults
Jessica A. Chichester et al.
VIRUSES-BASEL (2012)
109 The Immunogenicity and Safety of a Novel Staphylococcus Aureus Vaccine (V710) in Adults with End-Stage Renal Disease Receiving Hemodialysis -A Phase IIA Study
Moustafa Moustafa et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
Aluminium-based adjuvants should not be used as placebos in clinical trials
Christopher Exley
VACCINE (2011)
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial
Gerald Aichinger et al.
VACCINE (2011)
Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens
David M. Asmuth et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
Xiao-Feng Liang et al.
LANCET (2010)
Phase I Study of Safety and Immunogenicity of an Escherichia coli-Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults
Bruce K. Brown et al.
PLOS ONE (2010)
Role of adjuvants in modeling the immune response
Darrick Carter et al.
CURRENT OPINION IN HIV AND AIDS (2010)
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Aβ AFFITOPES as active vaccines in the treatment of Alzheimer's disease: preliminary results of two phase I studies
A. Kutzelnigg et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
A Novel Influenza A (H1N1) Vaccine in Various Age Groups.
Feng-Cai Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents
Lisa A. Jackson et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations
Karl G. Nicholson et al.
VACCINE (2009)
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up
Olimpia Longo et al.
VACCINE (2009)
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults
Wendy A. Keitel et al.
VACCINE (2009)
The preventive phase I trial with the HIV-1 Tat-based vaccine
Barbara Ensoli et al.
VACCINE (2009)
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults
Rebecca C. Brady et al.
VACCINE (2009)
A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine
Rebecca J. Cox et al.
VACCINE (2009)
A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age
Joanne M. Langley et al.
VACCINE (2009)
Mechanism of action of licensed vaccine adjuvants
Elaine Tritto et al.
VACCINE (2009)
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase I-II randomized clinical trial
Wendy A. Keitel et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
David I. Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines - Nonadjuvanted vaccine or vaccine adjuvanted with alum - Given concomitantly with influenza vaccine to high-risk elderly individuals
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture
Hartmut J. Ehrlich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults
Terry M. Nolan et al.
VACCINE (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults
James D. Campbell et al.
HUMAN VACCINES (2007)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro
GL Morefield et al.
VACCINE (2005)
Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence
T Jefferson et al.
LANCET INFECTIOUS DISEASES (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Effect of monophosphoryl lipid A (MPL®) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers
L Vernacchio et al.
VACCINE (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant
T Wuorimaa et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines
LC Paoletti et al.
INFECTION AND IMMUNITY (2001)
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans
TG Evans et al.
VACCINE (2001)
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
CD Harro et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Safety and immunogenicity of increasing doses of a Clostridium difficile toroid vaccine administered to healthy adults
KL Kotloff et al.
INFECTION AND IMMUNITY (2001)
Share Paper
